Targeting receptor tyrosine kinase signaling in acute myeloid leukemia

Critical Reviews in Oncology/Hematology

Volumn 63, Issue 3, 2007, Pages 215-230

  Doepfner, Kathrin T ^a   Boller, Danielle ^a   Arcaro, Alexandre ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

AML; c Kit; Flt3; IGF IR; mTOR; PI3K; Receptor tyrosine kinase

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; ANTINEOPLASTIC AGENT; CD135 ANTIGEN; CEP 701; EVEROLIMUS; GEFITINIB; IC 87114; IMATINIB; KP 372 1; LESTAURTINIB; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE; PD 186352; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; RAPAMYCIN; SEMAXANIB; SOMATOMEDIN RECEPTOR; SORAFENIB; STEM CELL FACTOR; SU 5614; SUNITINIB; TANDUTINIB; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; WORTMANNIN;

ACUTE GRANULOCYTIC LEUKEMIA; CARCINOGENESIS; CELL DIFFERENTIATION; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ACUTE DISEASE; DRUG DELIVERY SYSTEMS; HUMANS; LEUKEMIA, MYELOID; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 34547202520     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2007.05.005     Document Type: Review

References (125)

1. Deschler B., and Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 107 (2006) 2099-2107
2. Kolitz J.E. Current therapeutic strategies for acute myeloid leukaemia. Br J Haematol 134 (2006) 555-572
3. Estey E., and Dohner H. Acute myeloid leukaemia. Lancet 368 (2006) 1894-1907
4. Steffen B., Muller-Tidow C., Schwable J., Berdel W.E., and Serve H. The molecular pathogenesis of acute myeloid leukemia. Crit Rev Oncol Hematol 56 (2005) 195-221
5. Kelly L.M., and Gilliland D.G. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 3 (2002) 179-198
6. Hiddemann W., Spiekermann K., Buske C., et al. Towards a pathogenesis-oriented therapy of acute myeloid leukemia. Crit Rev Oncol Hematol 56 (2005) 235-245
7. Frohling S., Scholl C., Gilliland D.G., and Levine R.L. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 23 (2005) 6285-6295
8. Tenen D.G. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 3 (2003) 89-101
9. Martelli A.M., Nyakern M., Tabellini G., et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 20 (2006) 911-928
10. Wechsler J., Greene M., McDevitt M.A., et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 32 (2002) 148-152
11. Kurkjian C., Patel S., Kamble R., Dunn S.T., Kern W., and Kharfan-Dabaja M.A. Acute promyelocytic leukemia and constitutional trisomy 21. Cancer Genet Cytogenet 165 (2006) 176-179
12. Magalhaes I.Q., Splendore A., Emerenciano M., Figueiredo A., Ferrari I., and Pombo-de-Oliveira M.S. GATA1 mutations in acute leukemia in children with Down syndrome. Cancer Genet Cytogenet 166 (2006) 112-116
13. Gurbuxani S., Vyas P., and Crispino J.D. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood 103 (2004) 399-406
14. Hubbard S.R., Mohammadi M., and Schlessinger J. Autoregulatory mechanisms in protein-tyrosine kinases. J Biol Chem 273 (1998) 11987-11990
15. Hunter T. The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. Philos Trans R Soc Lond B Biol Sci 353 (1998) 583-605
16. Schlessinger J. Signal transduction by allosteric receptor oligomerization. Trends Biochem Sci 13 (1988) 443-447
17. Riedel H., Dull T.J., Honegger A.M., Schlessinger J., and Ullrich A. Cytoplasmic domains determine signal specificity, cellular routing characteristics and influence ligand binding of epidermal growth factor and insulin receptors. EMBO J 8 (1989) 2943-2954
18. Jiang G., and Hunter T. Receptor signaling: when dimerization is not enough. Curr Biol 9 (1999) R568-R571
19. Schaffhausen B. SH2 domain structure and function. Biochim Biophys Acta 1242 (1995) 61-75
20. Zhou M.M., and Fesik S.W. Structure and function of the phosphotyrosine binding (PTB) domain. Prog Biophys Mol Biol 64 (1995) 221-235
21. Yamamoto K., Altschuler D., Wood E., Horlick K., Jacobs S., and Lapetina E.G. Association of phosphorylated insulin-like growth factor-I receptor with the SH2 domains of phosphatidylinositol 3-kinase p85. J Biol Chem 267 (1992) 11337-11343
22. Myers Jr. M.G., Sun X.J., Cheatham B., et al. IRS-1 is a common element in insulin and insulin-like growth factor-I signaling to the phosphatidylinositol 3'-kinase. Endocrinology 132 (1993) 1421-1430
23. Vanhaesebroeck B., Leevers S.J., Panayotou G., and Waterfield M.D. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 22 (1997) 267-272
24. Peruzzi F., Prisco M., Dews M., et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 19 (1999) 7203-7215
25. Katso R., Okkenhaug K., Ahmadi K., White S., Timms J., and Waterfield M.D. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17 (2001) 615-675
26. Seger R., and Krebs E.G. The MAPK signaling cascade. FASEB J 9 (1995) 726-735
27. Hunter T., and Sefton B.M. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc Natl Acad Sci USA 77 (1980) 1311-1315
28. Nakao M., Yokota S., Iwai T., et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10 (1996) 1911-1918
29. Yamamoto Y., Kiyoi H., Nakano Y., et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97 (2001) 2434-2439
30. Gilliland D.G., and Griffin J.D. Role of FLT3 in leukemia. Curr Opin Hematol 9 (2002) 274-281
31. Stirewalt D.L., and Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 3 (2003) 650-665
32. Ridge S.A., Worwood M., Oscier D., Jacobs A., and Padua R.A. FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc Natl Acad Sci USA 87 (1990) 1377-1380
33. Rambaldi A., Wakamiya N., Vellenga E., et al. Expression of the macrophage colony-stimulating factor and c-fms genes in human acute myeloblastic leukemia cells. J Clin Invest 81 (1988) 1030-1035
34. Padua R.A., Guinn B.A., Al-Sabah A.I., et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia 12 (1998) 887-892
35. Beghini A., Peterlongo P., Ripamonti C.B., et al. C-kit mutations in core binding factor leukemias. Blood 95 (2000) 726-727
36. Kuriu A., Ikeda H., Kanakura Y., et al. Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-oncogene c-kit product. Blood 78 (1991) 2834-2840
37. Farr C.J., Saiki R.K., Erlich H.A., McCormick F., and Marshall C.J. Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. Proc Natl Acad Sci USA 85 (1988) 1629-1633
38. Bartram C.R., Ludwig W.D., Hiddemann W., et al. Acute myeloid leukemia: analysis of ras gene mutations and clonality defined by polymorphic X-linked loci. Leukemia 3 (1989) 247-256
39. Hayakawa F., Towatari M., Kiyoi H., et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19 (2000) 624-631
40. Pendergast A.M., Quilliam L.A., Cripe L.D., et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75 (1993) 175-185
41. Birkenkamp K.U., Geugien M., Lemmink H.H., Kruijer W., and Vellenga E. Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia 15 (2001) 1923-1931
42. Bromberg J.F., Wrzeszczynska M.H., Devgan G., et al. Stat3 as an oncogene. Cell 98 (1999) 295-303
43. Ning Z.Q., Li J., and Arceci R.J. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood 97 (2001) 3559-3567
44. Lacronique V., Boureux A., Valle V.D., et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278 (1997) 1309-1312
45. Peeters P., Raynaud S.D., Cools J., et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90 (1997) 2535-2540
46. Shimon I., and Shpilberg O. The insulin-like growth factor system in regulation of normal and malignant hematopoiesis. Leuk Res 19 (1995) 233-240
47. Neri L.M., Borgatti P., Tazzari P.L., et al. The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells. Mol Cancer Res 1 (2003) 234-246
48. Grandage V.L., Gale R.E., Linch D.C., and Khwaja A. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 19 (2005) 586-594
49. Xu Q., Simpson S.E., Scialla T.J., Bagg A., and Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102 (2003) 972-980
50. Druker B.J. Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opin Pharmacother 4 (2003) 963-971
51. Lyman S.D., and Williams D.E. Biology and potential clinical applications of flt3 ligand. Curr Opin Hematol 2 (1995) 177-181
52. Carow C.E., Levenstein M., Kaufmann S.H., et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 87 (1996) 1089-1096
53. Griffin J.D. Point mutations in the FLT3 gene in AML. Blood 97 (2001) 2193A
54. Smolich B.D., Yuen H.A., West K.A., Giles F.J., Albitar M., and Cherrington J.M. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 97 (2001) 1413-1421
55. Yee K.W., O'Farrell A.M., Smolich B.D., et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood 100 (2002) 2941-2949
56. Giles F.J., Stopeck A.T., Silverman L.R., et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 102 (2003) 795-801
57. O'Farrell A.M., Foran J.M., Fiedler W., et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 9 (2003) 5465-5476
58. O'Farrell A.M., Yuen H.A., Smolich B., et al. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk Res 28 (2004) 679-689
59. Fiedler W., Mesters R., Tinnefeld H., et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 102 (2003) 2763-2767
60. Fiedler W., Serve H., Dohner H., et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105 (2005) 986-993
61. Mesters R.M., Padro T., Bieker R., et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 98 (2001) 241-243
62. O'Farrell A.M., Abrams T.J., Yuen H.A., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101 (2003) 3597-3605
63. Weisberg E., Boulton C., Kelly L.M., et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1 (2002) 433-443
64. George P., Bali P., Cohen P., et al. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res 64 (2004) 3645-3652
65. Stone R.M., DeAngelo D.J., Klimek V., et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor PKC412. Blood 105 (2005) 54-60
66. Levis M., Allebach J., Tse K.F., et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 99 (2002) 3885-3891
67. Knapper S., Mills K.I., Gilkes A.F., Austin S.J., Walsh V., and Burnett A.K. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood 108 (2006) 3494-3503
68. Smith B.D., Levis M., Beran M., et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103 (2004) 3669-3676
69. Knapper S., Burnett A.K., Littlewood T., et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108 (2006) 3262-3270
70. Deangelo D.J., Stone R.M., Heaney M.L., et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 108 (2006) 3674-3681
71. Kelly L.M., Yu J.C., Boulton C.L., et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 1 (2002) 421-432
72. Wang C., Curtis J.E., Geissler E.N., McCulloch E.A., and Minden M.D. The expression of the proto-oncogene C-kit in the blast cells of acute myeloblastic leukemia. Leukemia 3 (1989) 699-702
73. Kanakura Y., Ikeda H., Kitayama H., Sugahara H., and Furitsu T. Expression, function and activation of the proto-oncogene c-kit product in human leukemia cells. Leuk Lymphoma 10 (1993) 35-41
74. Care R.S., Valk P.J., Goodeve A.C., et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 121 (2003) 775-777
75. Gari M., Goodeve A., Wilson G., et al. c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 105 (1999) 894-900
76. Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., and Zigler A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96 (2000) 925-932
77. Fang G., Kim C.N., Perkins C.L., et al. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 96 (2000) 2246-2253
78. Scappini B., Onida F., Kantarjian H.M., et al. Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells. Clin Cancer Res 7 (2001) 3884-3893
79. Cammenga J., Horn S., Bergholz U., et al. Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. Blood 106 (2005) 3958-3961
80. Cortes J., Giles F., O'Brien S., et al. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer 97 (2003) 2760-2766
81. Kindler T., Breitenbuecher F., Marx A., et al. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood 103 (2004) 3644-3654
82. Ito K., Tominaga K., Suzuki T., Jinnai I., and Bessho M. Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia. Int J Hematol 81 (2005) 242-245
83. Jentsch-Ullrich K., Pelz A.F., Braun H., et al. Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib. Haematologica 89 (2004) ECR15
84. Pompetti F., Spadano A., Sau A., et al. Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate. Leuk Res 31 (2007) 563-567
85. Viniou N.A., Vassilakopoulos T.P., Giakoumi X., Mantzouranis M., and Pangalis G.A. Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1+ acute myeloid leukemia. Eur J Haematol 72 (2004) 58-60
86. Yamaguchi M., and Konishi I. Successful treatment with imatinib mesylate for Philadelphia chromosome-positive refractory acute myeloid leukemia. Rinsho Ketsueki 44 (2003) 254-256
87. Cairoli R., Beghini A., Morello E., et al. Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases. Leuk Res 29 (2005) 397-400
88. Kindler T., Breitenbuecher F., Marx A., et al. Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML. Blood 101 (2003) 2960-2962
89. Schittenhelm M., Aichele O., Krober S.M., Brummendorf T., Kanz L., and Denzlinger C. Complete remission of third recurrence of acute myeloid leukemia after treatment with imatinib (STI-571). Leuk Lymphoma 44 (2003) 1251-1253
90. Kato H., Faria T.N., Stannard B., Roberts Jr. C.T., and LeRoith D. Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (alpha IR-3). J Biol Chem 268 (1993) 2655-2661
91. Hizuka N., Sukegawa I., Takano K., et al. Characterization of insulin-like growth factor I receptors on human erythroleukemia cell line (K-562 cells). Endocrinol Jpn 34 (1987) 81-88
92. Sukegawa I., Hizuka N., Takano K., Asakawa K., and Shizume K. Decrease in IGF-I binding sites on human promyelocytic leukemia cell line (HL-60) with differentiation. Endocrinol Jpn 34 (1987) 365-372
93. Khandwala H.M., McCutcheon I.E., Flyvbjerg A., and Friend K.E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21 (2000) 215-244
94. Abe S., Funato T., Takahashi S., et al. Increased expression of insulin-like growth factor i is associated with Ara-C resistance in leukemia. Tohoku J Exp Med 209 (2006) 217-228
95. Yasui H., Hideshima T., Richardson P.G., and Anderson K.C. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol 132 (2006) 385-397
96. Mitsiades C.S., Mitsiades N.S., McMullan C.J., et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5 (2004) 221-230
97. Guerreiro A.S., Boller D., Doepfner K.T., and Arcaro A. IGF-IR: potential role in antitumor agents. Drug News Perspect 19 (2006) 261-272
98. Osaki M., Oshimura M., and Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9 (2004) 667-676
99. Min Y.H., Eom J.I., Cheong J.W., et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 17 (2003) 995-997
100. Kubota Y., Ohnishi H., Kitanaka A., Ishida T., and Tanaka T. Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation. Leukemia 18 (2004) 1438-1440
101. Zhao S., Konopleva M., Cabreira-Hansen M., et al. Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia 18 (2004) 267-275
102. O'Gorman D.M., McKenna S.L., McGahon A.J., Knox K.A., and Cotter T.G. Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals. Leukemia 14 (2000) 602-611
103. Zeng Z., Samudio I.J., Zhang W., et al. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res 66 (2006) 3737-3746
104. Cheong J.W., Eom J.I., Maeng H.Y., et al. Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome. Br J Haematol 122 (2003) 454-456
105. Sujobert P., Bardet V., Cornillet-Lefebvre P., et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106 (2005) 1063-1066
106. Recher C., Beyne-Rauzy O., Demur C., et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105 (2005) 2527-2534
107. Schreiber S.L. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251 (1991) 283-287
108. Hidalgo M., and Rowinsky E.K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19 (2000) 6680-6686
109. Mohi M.G., Boulton C., Gu T.L., et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 101 (2004) 3130-3135
110. Hahn M., Li W., Yu C., Rahmani M., Dent P., and Grant S. Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Mol Cancer Ther 4 (2005) 457-470
111. Towatari M., Iida H., Tanimoto M., Iwata H., Hamaguchi M., and Saito H. Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia 11 (1997) 479-484
112. Kim S.C., Hahn J.S., Min Y.H., Yoo N.C., Ko Y.W., and Lee W.J. Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1. Blood 93 (1999) 3893-3899
113. Milella M., Estrov Z., Kornblau S.M., et al. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 99 (2002) 3461-3464
114. Lunghi P., Tabilio A., Dall'Aglio P.P., et al. Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia 17 (2003) 1783-1793
115. Wu J., Wong W.W., Khosravi F., Minden M.D., and Penn L.Z. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 64 (2004) 6461-6468
116. James J.A., Smith M.A., Court E.L., et al. An investigation of the effects of the MEK inhibitor U0126 on apoptosis in acute leukaemia. Hematol J 4 (2003) 427-432
117. Tong F.K., Chow S., and Hedley D. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry B Clin Cytom 70 (2006) 107-114
118. Sebti S.M., and Hamilton A.D. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 19 (2000) 6584-6593
119. Korycka A., Smolewski P., and Robak T. The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro. Eur J Haematol 73 (2004) 418-426
120. Karp J.E., Lancet J.E., Kaufmann S.H., et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 97 (2001) 3361-3369
121. Lancet J.E., Gojo I., Gotlib J., et al. A phase II study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 109 (2007) 1387-1394
122. Cortes J., Faderl S., Estey E., et al. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J Clin Oncol 23 (2005) 2805-2812
123. Stegmaier K., Corsello S.M., Ross K.N., Wong J.S., Deangelo D.J., and Golub T.R. Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood 106 (2005) 2841-2848
124. Milella M., Kornblau S.M., Estrov Z., et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 108 (2001) 851-859
125. Roboz G.J., Giles F.J., List A.F., et al. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia 20 (2006) 952-957